Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and [beta]-amyloid?

• Published in: Alzheimer's Research & Therapy 2022, Vol.14 (1)
• Main Authors: Akinci, Muge, Sánchez-Benavides, Gonzalo, Brugulat-Serrat, Anna, Peéa-Gómez, Cleofé, Palpatzis, Eleni, Shekari, Mahnaz, Deulofeu, Carme, Fuentes-Julian, Sherezade, Salvadó, Gemma, González-de-Echávarri, José Maria, Suárez-Calvet, Marc, Minguillón, Carolina, Fauria, Karine, Molinuevo, José Luis, Gispert, Juan Domingo, Grau-Rivera, Oriol, Arenaza-Urquijo, Eider M, Beteta, Annabella, Cacciaglia, Raffaele, Caéas, Alba, Cumplido, Irene, Dominguez, Ruth, Emilio, Maria, Falcon, Carles, Hernandez, Laura, Huesa, Gema, Huguet, Jordi, Marne, Paula, Menchón, Tania, Operto, Grégory, Polo, Albina, Rodríguez-Fernández, Blanca, Pradas, Sandra, Sadeghi, Iman, Soteras, Anna, Stankeviciute, Laura, Vilanova, Marc, Vilor-Tejedor, Natalia
• Format: Report
• Language: English
• Subjects: Amyloid beta-protein; Analysis; Care and treatment; Causes of; Depression, Mental; Diagnosis; Epidemics; Health aspects; Measurement; Neuropsychological tests; Psychological aspects; Stress (Psychology); United Kingdom
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-022-01068-7

Background The COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity of SCD and anxious/depressive symptoms during confinement and the underlying mechanisms. Methods Two hundred fifty cognitively unimpaired participants completed the Hospital Anxiety and Depression Scale (HADS) and SCD-Questionnaire (SCD-Q) and underwent amyloid-[beta] positron emission tomography imaging with [.sup.18F] flutemetamol (N = 205) on average 2.4 ([+ or -] 0.8) years before the COVID-19 confinement. During the confinement, participants completed the HADS, Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), and an ad hoc questionnaire on worries (access to primary products, self-protection materials, economic situation) and lifestyle changes (sleep duration, sleep quality, eating habits). We investigated stress-related measurements, worries, and lifestyle changes in relation to SCD. We then conducted an analysis of covariance to investigate the association of SCD-Q with HADS scores during the confinement while controlling for pre-confinement anxiety/depression scores and demographics. Furthermore, we introduced amyloid-[beta] positivity, PSS, and BRS in the models and performed mediation analyses to explore the mechanisms explaining the association between SCD and anxiety/depression. Results In the whole sample, the average SCD-Q score was 4.1 ([+ or -] 4.4); 70 (28%) participants were classified as SCD, and 26 (12.7%) were amyloid-[beta]-positive. During the confinement, participants reporting SCD showed higher PSS (p = 0.035) but not BRS scores (p = 0.65) than those that did not report SCD. No differences in worries or lifestyle changes were observed. Higher SCD-Q scores showed an association with greater anxiety/depression scores irrespective of pre-confinement anxiety/depression levels (p = 0.002). This association was not significant after introducing amyloid-[beta] positivity and stress-related variables in the model (p = 0.069). Amyloid-[beta] positivity and PSS were associated with greater HADS irrespective of pre-confinement anxiety/depression scores (p = 0.023; p < 0.001). The association of SCD-Q with HADS was mediated by PSS (p = 0.01). Conclusions Higher intensity of SCD, amyloid-[beta] positivity, and stress perception showed independent associations with anxious/depressive symptoms during the COVID-19 confine